Form 10-Q Allogene Therapeutics, For: Sep 30
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Acknowledges the Passing of Founding Board Member David BondermanGlobeNewswire
- Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - Valued at $1.16 Billion in 2024, the Industry is Forecast to Generate Revenues of $1.69 Billion by 2028 [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? [Yahoo! Finance]Yahoo! Finance
ALLO
Earnings
- 11/7/24 - Beat
ALLO
Sec Filings
- 12/10/24 - Form 4
- 12/9/24 - Form 4
- 12/9/24 - Form 144
- ALLO's page on the SEC website